Click Here for 5% Off Your First Aladdin Purchase!

Catumaxomab (anti-CD3&EpCAM) - Primary antibody, specific to CD3E; EPCAM, Mouse IgG2a, Antibody of CD3e

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥90%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity≥90% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Mouse IgG2A CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Species reactivity(Reacts with): Human,Mouse
  • Isotype: Mouse IgG2a
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab175489
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175489-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$119.90
Ab175489-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$559.90
Ab175489-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,399.90
Ab175489-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,239.90

Purity≥90% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Mouse IgG2A CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameCatumaxomab (anti-CD3&EpCAM) - Primary antibody, specific to CD3E; EPCAM, Mouse IgG2a
SynonymsL01XC09;Removab
Specifications & PurityLow Endotoxin, Azide Free, Validated, Recombinant, Carrier Free, ExactAb™, ≥90%(SDS-PAGE&SEC), Lot by Lot
SpecificityCD3E; EPCAM
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeCROSS-LINKING AGENT
Mechanism of actionAntibody of CD3e
Product Description

Catumaxomab (anti-CD3&EpCAM), a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab (anti-CD3&EpCAM) region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab (anti-CD3&EpCAM) can be used for anti-tumor research, especially epithelial cancers.
Purity
≥90% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg
Protein Function
CD3: The CD3 complex mediates signal transduction.
EpCAM:May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E

Product Properties

IsotypeMouse IgG2a
Light Chain Typekappa
SDS-PAGE146.73 kDa
Purification MethodProtein A purified
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS509077-98-9

Associated Targets

EPCAM Tbio Epithelial cell adhesion molecule 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CD3E Tclin T-cell surface glycoprotein CD3 epsilon chain 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H.  (1999)  Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing..  J Immunol,  163  (3): (1246-52).  [PMID:10415020]
2. Riesenberg R, Buchner A, Pohla H, Lindhofer H.  (2001)  Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3)..  J Histochem Cytochem,  49  (7): (911-7).  [PMID:11410615]
3. Ruf P, Lindhofer H.  (2001)  Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody..  Blood,  98  (8): (2526-34).  [PMID:11588051]
4. Shen J, Zhu Z.  (2008)  Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer..  Curr Opin Mol Ther,  10  (3): (273-84).  [PMID:18535935]
5. Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A.  (2007)  Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study..  Cancer Immunol Immunother,  56  (10): (1637-44).  [PMID:17410361]
6. Linke R, Klein A, Seimetz D.  (2010)  Catumaxomab: clinical development and future directions..  MAbs,  (2): (129-36).  [PMID:20190561]
7. Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H.  (2010)  Structural and functional characterization of the trifunctional antibody catumaxomab..  MAbs,  (3): (309-19).  [PMID:20418662]

Solution Calculators